PMID- 29987370
OWN - NLM
STAT- MEDLINE
DCOM- 20190809
LR  - 20190809
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Linking)
VI  - 82
IP  - 3
DP  - 2018 Sep
TI  - Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent 
      chemoradiotherapy for locally advanced lung squamous cell carcinoma.
PG  - 505-510
LID - 10.1007/s00280-018-3640-6 [doi]
AB  - OBJECTIVE: The aim of this study was to evaluate the efficacy and toxicities of 
      liposome-paclitaxel and carboplatin concurrent with radiotherapy for locally 
      advanced lung squamous cell carcinoma (LSCC). METHODS: The clinical data of 38 
      patients with locally advanced LSCC treated with liposome-paclitaxel based 
      concurrent chemoradiotherapy were collected and reviewed. The overall response, 
      toxicities, progression-free survival and overall survival were analyzed with 
      SPSS software. RESULT: The efficacy of treatment was classified as complete 
      remission in 4 cases (10.5%), partial remission in 22 cases (57.9%) and stable 
      disease in 12 cases (31.6%). The objective response rate was 68.4% (26/38). The 
      most common types of hematological toxicities were anemia (65.7%) and leukopenia 
      (57.9%), but all the events were transient. No paclitaxel-induced allergic 
      reactions occurred during the treatment. The median PFS and OS time were 17.0 and 
      29.0 months. CONCLUSIONS: Liposome-paclitaxel and carboplatin concurrent with 
      radiotherapy showed a significant antitumor effect to LSCC with manageable 
      toxicities. Further clinical investigation are warranted to evaluate the efficacy 
      of this regimen.
FAU - Chen, Guofu
AU  - Chen G
AD  - Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
AD  - Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang 
      Cancer Hospital, 1 Banshandong Road, Hangzhou, 310022, Zhejiang, China.
FAU - Sheng, Liming
AU  - Sheng L
AD  - Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. 
      m05shengliming@126.com.
AD  - Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang 
      Cancer Hospital, 1 Banshandong Road, Hangzhou, 310022, Zhejiang, China. 
      m05shengliming@126.com.
FAU - Du, Xianghui
AU  - Du X
AD  - Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. 
      duxianghui88@aliyun.com.
AD  - Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang 
      Cancer Hospital, 1 Banshandong Road, Hangzhou, 310022, Zhejiang, China. 
      duxianghui88@aliyun.com.
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180709
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Liposomes)
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Carboplatin/administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiotherapy
MH  - Carcinoma, Squamous Cell/*drug therapy/pathology/*radiotherapy
MH  - Chemoradiotherapy
MH  - Female
MH  - Humans
MH  - Liposomes/administration & dosage/adverse effects
MH  - Lung Neoplasms/*drug therapy/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Paclitaxel/administration & dosage/adverse effects
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Radiotherapy, Intensity-Modulated
OTO - NOTNLM
OT  - Chemoradiotherapy
OT  - Liposome-paclitaxel
OT  - Lung squamous cell carcinoma
OT  - Non-small cell lung carcinoma
EDAT- 2018/07/11 06:00
MHDA- 2019/08/10 06:00
CRDT- 2018/07/11 06:00
PHST- 2018/05/03 00:00 [received]
PHST- 2018/07/03 00:00 [accepted]
PHST- 2018/07/11 06:00 [pubmed]
PHST- 2019/08/10 06:00 [medline]
PHST- 2018/07/11 06:00 [entrez]
AID - 10.1007/s00280-018-3640-6 [pii]
AID - 10.1007/s00280-018-3640-6 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2018 Sep;82(3):505-510. doi: 
      10.1007/s00280-018-3640-6. Epub 2018 Jul 9.